According to Dessai et al., aggressive prostate cancer is facilitated by the increased activity of mitochondrial aconitase (ACO2), which results from the repression of mitochondrial SIRT3 transcription by the androgen receptor and its co-regulator steroid receptor coactivator-2 (SRC-2) [141]. The gene discussed is ACO2; the disease is prostate carcinoma.